Showing 6511-6520 of 7019 results for "".
- XOMA Gains Orphan Drug Designation to Treat Pyoderma Gangrenosumhttps://practicaldermatology.com/news/20140225-xoma_gains_orphan_drug_designation_to_treat_pyoderma_gangrenosum/2459332/The FDA approved XOMA Corporation's IL-1 beta antibody gevokizumab for the treatment of pyoderma gangrenosum (PG) under an orphan drug designation. PG is a rare disorder of expanding, painful skin ulcers, which affects one in about 100,000 people. "Selecting pyoderma gangrenosum as our n
- Onset Dermatologics Launches New Strength of Minocinhttps://practicaldermatology.com/news/20140225-onset_dermatologics_launches_new_strength_of_minocin/2459333/Onset Dermatologics launced a 75mg strength of Minocin (minocycline hydrochloride) Pellet-Filled Capsules, a tetracycline class antibiotic medicine used to treat infections caused by bacteria. Minocin may be used along with other agents in the treatment of severe acne.
- Video Intervention May Increase Skin Cancer Diagnosis in Older Menhttps://practicaldermatology.com/news/20140224-video_intervention_may_increase_skin_cancer_diagnosis_in_older_men/2459334/Showing men a video on skin self-examination and skin awareness may help to increase the number of patients who receive whole-body clinical skin examinations (CSEs) from their physicians, which could increase skin cancer diagnosis in older men, according to a study by Monika Jan
- DEKA Medical Receives FDA Clearance for the Synchro REPLA:Yhttps://practicaldermatology.com/news/20140213-deka_medical_receives_fda_clearance_for_the_synchro_replay/2459343/The FDA cleared DEKA Medical, Inc.'s Synchro REPLA:Y, an aesthetic workstation dedicated, but not limited, to high speed stable long-term, or permanent hair reduction, treatment of PFB, treatment of benign pigmented lesions, treatment of wrinkles and
- Revance Therapeutics Announces Pricing of Initial Public Offeringhttps://practicaldermatology.com/news/20140207-revance_therapeutics_announces_pricing_of_initial_public_offering/2459346/Revance Therapeutics, Inc., a specialty biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic indications, announced the pricing of its initial public offering of 6,000,000 shares of its common stock at a public offering price of $16.00 per share, befo
- CeraVe Launches Two Skin Care Productshttps://practicaldermatology.com/news/20140123-cerave_launches_two_skin_care_products/2459361/CeraVe has introduced the CeraVe Eye Repair Cream and CeraVe Intensive Stretch Marks Cream. The Eye Repair Cream combines three essential ceramides, to help repair and restore the delicate barrier around the eyes, with hydrating hyaluronic acid to help diminish fine lines and wrinkles. The Intensive
- Alma Lasers Debuts its 2014 Webinar Serieshttps://practicaldermatology.com/news/20140116-alma_lasers_debuts_its_2014_webinar_series/2459372/In a complimentary webinar series, industry experts will showcase their success building local market awareness to drive practice results. Spearheaded by Alma Lasers , the informative ses
- Caliber Imaging & Diagnostics Receives $1.4 Million Order for VivaScope® Systems From European Distributor MAVIG GmbHhttps://practicaldermatology.com/news/20140114-caliber_imaging__diagnostics_receives_14_million_order_for_vivascope_systems_from_european_distributor_mavig_gmbh/2459373/Caliber Imaging & Diagnostics (OTCQB:LCDX), formerly Lucid, Inc., announces receipt of $1.4 million in orders for VivaScope® systems from its European distributor MAVIG GmbH. These units are scheduled to be shipped in the first half of 2014. MAVIG has been Caliber's exclusive distributor in Europe f
- FDA Approves Combination Use of GSK's Mekinist® (trametinib) and Tafinlar® (dabrafenib)https://practicaldermatology.com/news/20140109-fda_approves_combination_use_of_gsks_mekinist_trametinib_and_tafinlar_dabrafenib/2459375/GlaxoSmithKline plc [LSE/NYSE: GSK] has received FDA approval of Mekinist® (trametinib) for use in combination with Tafinlar® (dabrafenib) for the treatment of patients with unresectable melanoma or metastatic melanoma with BRAF V600E or V600K mutation
- Suneva Medical Announces 12-Month Safety Results From Artefill® Acne Scar Studyhttps://practicaldermatology.com/news/20140107-suneva_medical_announces_12-month_safety_results_from_artefill_acne_scar_study/2459379/Suneva Medical Inc. announced the 12-month follow-up data from its randomized, double-blinded, multi-center, Pivotal acne scar investigational study evaluating the safety and efficacy of ArteFillâ, a dermal filler, to treat acne scars.